Chwee Teck Lim's Biography

Chwee Teck Lim, NUS Society Chair Professor, Department of Biomedical Engineering, Institute for Health Innovation & Technology (iHealthtech), Mechanobiology Institute, National University of Singapore

Professor Chwee Teck LIM is the NUSS Chair Professor and Director of the Institute for Health Innovation and Technology at the National University of Singapore. He has coauthored over 500 journal publications and cofounded six startups with one public listed in 2018. Prof Lim is an elected Fellow of nine academies and organizations including the Royal Society UK, US National Academy of Inventors, IUPESM, AIMBE, IAMBE, Singapore National Academy of Science and Academy of Engineering Singapore. He has garnered numerous research awards including Nature Lifetime Achievement Award for Mentoring in Science, Highly Cited Researcher, Asia’s Most Influential Scientist Award, Wall Street Journal Asian Innovation Award (Gold) and the President's Technology Award.

Microfluidic Enrichment for Single Cancer Cell Analysis

Monday, 20 March 2017 at 16:30

Add to Calendar ▼2017-03-20 16:30:002017-03-20 17:30:00Europe/LondonMicrofluidic Enrichment for Single Cancer Cell AnalysisSELECTBIOenquiries@selectbiosciences.com

Tumor heterogeneity is currently a major hindrance to cancer diagnosis and treatment. Here, microfluidic technology is used to enrich and enable probing of the molecular heterogeneity of single circulating tumor cells so as to obtain patient derived information for the personalized treatment of cancer patients.

Tumor heterogeneity is a general trait of cancer which has proven to be a major hindrance in cancer classification, diagnosis and treatment. Cancer can be classified loosely into a few distinct sub-types, but recent technological advances have begun to reveal the true extent of its heterogeneity. Single cell analysis is emerging as an important approach to detect variations in morphology or genetic, proteomic and molecular expression. Here, we will present several novel microfluidic technologies to probe the heterogeneity of cancer patient derived circulating tumor cells (CTCs). These include detecting the proteolytic capability of each CTC to obtain hint of their invasiveness as well as identify unique actionable key driver mutations with aim of improving anticancer therapy. It is hope that this single cell analysis approach will not only lead to more precised treatment of cancer patients from the individually derived information of these tumor cells, but will also aid in the development of better drugs to combat this disease.

Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonExosomes and Extracellular Vesicles (EV): Research, Diagnostics and Therapeutics OpportunitiesSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors